Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.
Advanced Solid Tumours
DRUG: EXS21546
Safety of EXS21546 in combination with nivolumab., Incidence of treatment-emergent adverse events (TEAEs) and SAEs characterised by type, incidence, severity (graded by National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0), seriousness, timing and relationship to EXS21546 dosing., Through study completion, an average of 6 months|Dose-limiting toxicities (DLTs) of EXS21546 in combination with nivolumab., Incidence of dose limiting toxicities (DLTs) during Cycle 1 (initial 28 days) of treatment with escalating doses of EXS21546 in combination with an approved dose of nivolumab., Through dose escalation completion, an average of 6 months|Preliminary anti-tumoural activity of EXS21546 in combination with nivolumab., Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1., Through study completion, an average of 6 months|Treatment adherence of EXS21546 in combination with nivolumab., Number of doses recorded in the treatment diary., Through study completion, an average of 6 months|Tolerability of EXS21546 in combination with nivolumab., Frequency of dose interruptions, dose reductions and dose intensity achieved., Through study completion, an average of 6 months
A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor, nivolumab, in patients with advanced solid tumours, non small cell lung cancer and renal cell carcinoma.